These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16998718)

  • 1. Combination therapy.
    Martinelli V
    Neurol Sci; 2006 Sep; 27 Suppl 5():S350-4. PubMed ID: 16998718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy in multiple sclerosis.
    Fernández O
    J Neurol Sci; 2007 Aug; 259(1-2):95-103. PubMed ID: 17507031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy in multiple sclerosis.
    Milo R; Panitch H
    J Neuroimmunol; 2011 Feb; 231(1-2):23-31. PubMed ID: 21111490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M; Ghezzi A; Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
    Linker RA; Lee DH; Stangel M; Gold R
    Expert Rev Neurother; 2008 Nov; 8(11):1683-90. PubMed ID: 18986239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
    Frohman EM; Stüve O; Havrdova E; Corboy J; Achiron A; Zivadinov R; Sorensen PS; Phillips JT; Weinshenker B; Hawker K; Hartung HP; Steinman L; Zamvil S; Cree BA; Hauser S; Weiner H; Racke MK; Filippi M
    Arch Neurol; 2005 Oct; 62(10):1519-30. PubMed ID: 16216934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isobologram analysis of triple therapies.
    Niyazi M; Belka C
    Radiat Oncol; 2006 Oct; 1():39. PubMed ID: 17044920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Armstrong PW; Cannon CP; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2570-89. PubMed ID: 17502591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis.
    Shevchenko YL; Novik AA; Kuznetsov AN; Afanasiev BV; Lisukov IA; Kozlov VA; Rykavicin OA; Ionova TI; Melnichenko VY; Fedorenko DA; Kulagin AD; Shamanski SV; Ivanov RA; Gorodokin G
    Exp Hematol; 2008 Aug; 36(8):922-8. PubMed ID: 18468768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodology of clinical trials in multiple sclerosis.
    Mitsikostas DD
    Neurol Sci; 2006 Sep; 27 Suppl 5():S362-4. PubMed ID: 16998721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis.
    Correale J; Fiol M
    Curr Opin Mol Ther; 2009 Aug; 11(4):463-70. PubMed ID: 19649992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
    Hargrave D
    Br J Neurosurg; 2009 Aug; 23(4):351-63. PubMed ID: 19637006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.